Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin.

Seon Hwa LeeIksung ChoSeng-Chan YouMin-Jae ChaJee Suk Chang William D Kim Kyu Yong KoDae-Young KimJiwon SeoChi Young ShimGeu-Ru HongSeok-Min KangJong-Won HaSun-Young RhaHyo-Song Kim

Published in: Cancers (2022)

ICIs may increase the risk of CTRCD when used with cardiotoxic agents. CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS.

Keyphrases

cancer therapy
left ventricular
drug delivery
computed tomography
oxidative stress
pulmonary hypertension
heart failure